Japan Exchange
02:00:00 2024-06-14 am EDT
5-day change
1st Jan Change
5,723
JPY
-0.90%
+0.63%
+9.87%
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021
November 09, 2020 at 01:00 am EST
Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2021. For the year, the company expects net sales of JPY 200,200 million, operating profit of JPY 26,850 million, profit attributable of owners of parent of JPY 20,050 million or JPY 457.85 per share.
Transcript : Sawai Group Holdings Co., Ltd. - Special Call
Jun. 05
Transcript : Sawai Group Holdings Co., Ltd., 2024 Earnings Call, May 14, 2024
May. 14
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2024 and Fiscal Year Ending March 2025
May. 13
CI
Sawai Group Holdings Co., Ltd. Announces Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2025
May. 13
CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 26, 2024
May. 13
CI
Sawai Group Finalizes Sale of US Subsidiary
Apr. 03
MT
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..
Mar. 31
CI
Jefferies Adjusts Sawai Group’s Price Target to 5,000 Yen From 5,200 Yen, Keeps at Hold
Mar. 06
MT
Sawai Group Holdings Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2024
Feb. 13
CI
Sawai Group Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Feb. 13
CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million.
Jan. 15
CI
Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd.
Dec. 27
CI
Jefferies Adjusts Sawai’s Price Target to 4,500 Yen From 3,500 Yen, Keeps at Hold
Nov. 22
MT
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Nov. 10
CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024
Nov. 10
CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024
23-08-09
CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024
23-08-09
CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024
23-05-11
CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024
23-05-11
CI
Sawai Group Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-10
CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
23-02-12
CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
23-02-12
CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Second Quarter Ending September 30, 2022, Payable on December 2, 2022; Provides Dividend Guidance for the Year Ending March 31, 2023
22-11-08
CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
22-11-08
CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2023
22-08-10
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
More about the company
Last Close Price
5,775
JPY
Average target price
6,840
JPY
Spread / Average Target
+18.44%
Consensus
1st Jan change
Capi.
+9.87% 1.61B +51.54% 795B -7.20% 350B +18.67% 328B +7.48% 294B +17.54% 245B +1.02% 222B +11.18% 215B +3.64% 160B -3.96% 157B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SAWAI GROUP HOLDINGS CO., LTD. 
